Back to top

gene-editing: Archive

Sundeep Ganoria

Will AbbVie's Acquisition Spree Aid Pipeline Growth?

ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.

SNYPositive Net Change LLYPositive Net Change ABBVPositive Net Change

Sundeep Ganoria

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.

REGNPositive Net Change VRTXPositive Net Change NTLANegative Net Change CRSPNegative Net Change

Ahan Chakraborty

What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?

LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.

SNYPositive Net Change NVOPositive Net Change LLYPositive Net Change VERVNo Net Change

Sundeep Ganoria

Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?

CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field.

NVSPositive Net Change BMYPositive Net Change VRTXPositive Net Change BEAMNegative Net Change CRSPNegative Net Change

Ekta Bagri

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement

LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.

LLYPositive Net Change BEAMNegative Net Change NTLANegative Net Change CRSPNegative Net Change VERVNo Net Change

Zacks Equity Research

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly

VERV jumps on Eli Lilly's buyout offer, adding next-gen gene-editing therapies to the pharma giant's pipeline.

SNYPositive Net Change BMYPositive Net Change LLYPositive Net Change VERVNo Net Change